Aurinia Q2 2022 revenue up to $28.2M; net loss narrows to $0.25/share

Aurinia Pharmaceuticals Inc.

2022-Q2 EPS reported -$0.52 revenue$49,816,000

Q2 net product revenue $28.2M vs $6.6M YoY; six month revenue $49.8M.
Net loss $35.5M ($0.25/share) vs $47.0M ($0.37) in Q2 2021.
LUPKYNIS patients on treatment ~1,274 at June 30, up 19% from Q1 2022.
2022 net revenue guidance reaffirmed at $115-$135M.
Positive CHMP opinion in Europe; EC decision expected by end of Q3 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.